These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction. Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814 [No Abstract] [Full Text] [Related]
13. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient. Uber L; Cofer J; Baliga P; Rajagopalan PR Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818 [No Abstract] [Full Text] [Related]
14. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459 [TBL] [Abstract][Full Text] [Related]
15. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group. Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972 [No Abstract] [Full Text] [Related]
16. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289 [TBL] [Abstract][Full Text] [Related]
17. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation. Shen GK; Alfrey EJ; Knoppel CL; Dafoe DC; Scandling JD Transplantation; 1997 Sep; 64(6):931-3. PubMed ID: 9326425 [TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936 [TBL] [Abstract][Full Text] [Related]
19. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients. Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962 [TBL] [Abstract][Full Text] [Related]
20. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]